Voters would likely approve a measure to decriminalize psychedelic plants and fungi in the nation’s capital if organizers qualified it for the November ballot, a new poll shows.
But even getting the measure before Washington, D.C. voters may be a tall order as the coronavirus pandemic has hampered signature gathering efforts for the proposed initiative to make psilocybin, ayahuasca, ibogaine and other entheogens among the city’s lowest law enforcement priorities.
The new poll, commissioned by the Decriminalize Nature D.C. campaign, asked likely voters a series of questions about their support for the psychedelics reform measure.
When read the actual ballot text at the start of the survey, a bare majority—51 percent—said they were in favor, compared to 27 percent in opposition.
Support rose to 60 percent after voters were given more information about the measure’s provisions. That’s more than twice as many as said they oppose the reform, which stayed at 27 percent.
After being read pro and con arguments about the psychedelics decriminalization question, the final result was 59 percent in support to 32 percent in opposition.
“Despite the current public health crisis, D.C. voters have made clear that they are ready to change how D.C. approaches entheogens,” Melissa Lavasani, the proposer of the measure, said in a press release. “Now our campaign must make sure that voters have the opportunity to do so ”
The poll found that 10 percent of voters say they have personally used psilocybin or magic mushrooms, and 23 percent say that someone close to them has. When it comes to other substances that would be covered under the proposed ballot measure’s provisions, however, only single-digit percentages of voters say they or someone close to them has experience with ayahuasca, mescaline or iboga.
“This lack of direct personal experience underscores the need for public education about plant medicines, and their benefits for addressing these widespread mental health conditions,” a memo prepared by FM3 Research, which conducted the survey, says.
That said, majorities of voters say they or someone in their life has experienced anxiety or depression—and nearly a third know someone who has experienced PTSD—conditions which a growing body of research says can be treated with psychedelic therapy. Therefore, the activists behind the measure want to focus campaign ads on the therapeutic uses of the substances they are seeking to effectively decriminalize.
“In sum, the survey results show a clear path to victory for Initiative 81 with a strong campaign,” the polling memo says. “Despite very few voters having a personal experience with plant medicines like psilocybin, ayahuasca, iboga or mescaline, DC voters largely support a measure that would re-focus public safety resources on more important issues than possession of these substances.”
Activists in more than 100 U.S. cities are pursuing similar psychedelics reform campaigns, a movement that kicked off after Denver voters approved a psilocybin decriminalization ballot measure last year.
Shortly after that, the Oakland, California City Council passed a resolution covering a broad ranged of psychedelics. The Santa Cruz, California City Council follow suit in January by approving its own psychedelics decriminalization measure.
The results of the new D.C. poll are promising for the activists behind the measure, and bode well for a victory in November—if only they can get it on the ballot for voters to decide on.
The COVID-19 outbreak has made traditional in-person petitioning all but impossible as people are taking social distancing measures to prevent the further spread of the virus.
Members of Decriminalize Nature D.C.—several of whom were part of the successful effort to pass a marijuana legalization ballot measure in the District of Columbia in 2014—have pushed city officials to let them collect signatures electronically, but those calls have so far gone unheeded.
They have also asked to revise a current regulation that prevents voters from signing a ballot petition that they themselves are circulating, which in effect means that in order for someone to list their support there needs to be person-to-person contact as voters circulate their sheets for other people so sign.
With that regulation overturned, the campaign could simply mail petition sheets for individual voters to sign and return.
Washington, D.C. isn’t the only place where ballot petition efforts for drug policy reform campaigns have been impeded by the coronavirus outbreak.
An Arizona cannabis legalization campaign filed a lawsuit before the state Supreme Court that seeks the ability to use a current e-signature gathering system that is currently only available for individual political candidates and not ballot initiatives.
Nebraska medical cannabis activists have temporarily suspended signature gathering efforts and hope to resume after the pandemic.
Missouri activists recently ended their marijuana legalization campaign for 2020 because COVID-19 made signature gathering impossible.
Idaho activists suspended their medical cannabis ballot campaign, and a North Dakota effort to put a marijuana legalization measure on that state’s ballot also conceded that it was unlikely to succeed in 2020.
The new D.C. poll was conducted March 31-April 5, and involved 801 live telephone interviews with likely November 2020 voters. It has a margin of error of +/-4.0 percentage points.
Read the full results of the D.C. psychedelics decriminalization poll below:
California Senator Previews Next Steps For Psychedelics Bill And Says It’s A Step Toward Decriminalizing All Drugs
A California senator sponsoring a bill to legalize possession of psychedelics in the state says the proposal is a step toward eventually decriminalizing all drugs.
“We want to get there,” he said in a recent meeting with activists and researchers, though he added that it’s possible the broader reform would need to be decided by voters.
Sen. Scott Wiener (D) made the comments last week in a chat hosted by the Psychedelic and Entheogen Academic Council (PEAC), discussing next steps for his psychedelics legislation after it passed in the Senate earlier this month. He said advancing the measure in the Assembly will be “very challenging” due to a number of factors, but he sees progress in the legislature.
It’s also unclear where Gov. Gavin Newsom (D) stands on the reform, he said—though the governor has long been an outspoken opponent of the war on drugs.
“This is the first time that this idea has ever been introduced in the legislature,” Wiener said. “It’s a brand new idea” that “many of my colleagues have never interacted with.”
The bill originally included record sealing and resentencing provisions for people previously convicted of psychedelics possession offenses, but that language was removed in its last committee stop prior to the Senate floor vote as part of an amendment from the sponsor.
Wiener said the reasoning behind that deletion was that the policy “ended up generating a huge price tag” based on a fiscal analysis, but it could be addressed in separate legislation if the main bill passes.
Since clearing the Senate, SB 519 has been referred to two Assembly committees—Public Safety and Health—but the clock is ticking to move it this session. The senator said it must be heard by the panels by July 15, and then it would go the the Appropriations Committee, which would need to take action by late August.
If all goes well, Wiener told the PEAC members that a floor vote in the Assembly would happen in early September. Should the chamber approve it, the bill would go back to the Senate for concurrence on any amendments (or otherwise go right to Newson’s desk). The governor would need to receive the bill by September 10, and then he would have 30 days to act on it.
Assembly passage is far from a given, however. There are “rivalries” and “tensions” between the two chambers, Wiener said, despite the fact that they’re controlled by the same party.
Colleagues in the same chamber might be more willing to “give you a benefit of the doubt in helping you move forward bills,” he said. What’s more, members in the Assembly go up for reelection more frequently than in the Senate, making them less inclined to back novel legislation like the psychedelics proposal.
The senator said one possible amendment that could be expected in the Assembly would be to remove ketamine from the list of psychedelics that would be included in the reform.
“There are disagreements within the psychedelic world on it,” he said. “It might come out. My view as you keep things in until you have to make a give, and that’s one that we could potentially give on. You don’t want to spontaneously give on things without getting some ability to move the bill forward as a result.”
Mescaline, a psychoactive compound derived from peyote and other cacti, is another controversial psychedelic.
It was specifically excluded from the bill’s reform provisions in peyote-derived form, but the possession of the compound would be allowed if it comes from other plants such as “the Bolivian Torch Cactus, San Pedro Cactus, or Peruvian Torch Cactus.”
That decision on the peyote exclusion was informed by native groups who have strongly pushed back against decriminalizing the cacti for conservationist reasons and because of its sacred value for their communities.
If enacted into law, the bill would remove criminal penalties for possessing or sharing numerous psychedelics—including psilocybin mushrooms, DMT, ibogaine, LSD and MDMA—for adults 21 and older.
Marijuana Moment is already tracking more than 1,100 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.
Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.
The state Department of Public Health would be required to establish a working group “to study and make recommendations regarding possible regulatory systems that California could adopt to promote safe and equitable access to certain substances in permitted legal contexts.” Those recommendations would be due by January 1, 2024.
For psilocybin specifically, the legislation would repeal provisions in California statute that prohibit the cultivation or transportation of “any spores or mycelium capable of producing mushrooms or other material” that contain the psychoactive ingredient.
But this bill, Wiener emphasized at the beginning of the meeting, is ultimately an incremental step to ending the drug war.
“My view is we should be decriminalizing possession and use of all drugs—and we want to get there,” he said. “This is a step just like cannabis [legalization] was a step. And ultimately we may need to go to the voters for the broader drug decriminalization like Oregon.”
For the time being, however, the senator encouraged PEAC members in San Francisco, where lawmakers are more amenable to psychedelics reform, to reach out to people in other areas of the state to apply pressure on their representatives.
Meanwhile, a group of California activists announced plans earlier this year to put an initiative to legalize the use and retail sale of psilocybin on the state’s 2022 ballot. That group, Decriminalize California, said that it would first work to convince lawmakers to pursue reform and then take the issue directly to the people if the legislature fails to act.
The psychedelics effort in the California legislature, which Wiener first previewed back in November, comes as activists are stepping up the push to enact psychedelics reform locally in cities in the state and across the country. The bill notes those efforts in an explanation of the proposal.
The Northampton, Massachusetts City Council passed a resolution in April to deprioritize enforcement of laws against the possession, use and distribution of a wide range of psychedelics such as psilocybin and ayahuasca. It’s the third city in the state to advance the policy change, following Somerville and Cambridge.
These are some of the latest iterations of a national psychedelics reform movement that’s spread rapidly since Denver became the first city to decriminalize psilocybin mushrooms in 2019.
In Oregon, November’s election saw the passage of a historic initiatives to legalize psilocybin mushrooms for therapeutic purposes and more broadly decriminalize possession of all drugs.
The governor of Connecticut signed legislation last week that includes language requiring the state to carry out a study into the therapeutic potential of psilocybin mushrooms.
Texas lawmakers also recently sent their governor a bill to require the state study the medical benefits of psychedelics for military veterans.
A New York lawmaker introduced a bill this month that would require the state to establish an institute to similarly research the medical value of psychedelics.
In Oakland, the first city where a city council voted to broadly deprioritize criminalization of entheogenic substances, lawmakers approved a follow-up resolution in December that calls for the policy change to be adopted statewide and for local jurisdictions to be allowed to permit healing ceremonies where people could use psychedelics.
After Ann Arbor legislators passed a decriminalization resolution last year, a county prosecutor recently announced that his office will not be pursuing charges over possessing entheogenic plants and fungi—“regardless of the amount at issue.”
The Aspen, Colorado City Council discussed the therapeutic potential of psychedelics like psilocybin and proposals to decriminalize such substances at a meeting last month. But members said, as it stands, enacting a reform would be more better handled at the state level while entheogens remain strictly federally controlled.
Seattle lawmakers also recently sent a letter to members of a local task force focused on the opioid overdose epidemic, imploring the group to investigate the therapeutic potential of psychedelics like ayahuasca and ibogaine in curbing addiction.
Photo courtesy of Wikimedia/Mushroom Observer.
New Jersey Attorney General Cracks Down On ‘Gift’ Marijuana Schemes Involving Overpriced Snacks
The attorney general of New Jersey on Tuesday sent warning letters to companies that are effectively circumventing the state’s marijuana laws by “gifting” cannabis in exchange for non-marijuana-related purchases such as overpriced cookies, brownies and stickers.
Gifting is lawful between adults 21 and older under New Jersey’s adult-use cannabis law, but a number of businesses are allegedly taking advantage of that policy by giving away “free” cannabis products to those who purchase other items like snacks and baked goods.
No retail marijuana businesses have been licensed since the state enacted recreational legalization earlier this year, which followed voter approval of a reform initiative during the November 2020 election. Licensing regulations still need to be developed before adult-use shops can open.
Have you heard about businesses that “gift” marijuana w/ the purchase of snacks or other items? This isn’t the kind of cannabis business allowed by NJ’s new law. We’re warning these businesses to stop unlawful practices that could undercut the legal market.https://t.co/pYBODk12DY
— AG Gurbir Grewal (@NewJerseyOAG) June 15, 2021
“In legalizing adult-use cannabis in New Jersey, the Legislature made it clear they were creating a regulated market with restrictions on how that market operates,” Attorney General Gurbir Grewal said in a press release. “Instead of waiting for those regulations to be established, some vendors have decided to move forward on their own, in ways that the law does not allow.”
“Today we’re making it clear that we will not permit these entities to undermine the regulated cannabis marketplace the Legislature created or to compete unfairly with properly licensed cannabis businesses,” he said.
Four Sky High Munchies, Slumped Kitchen LLC, NJGreenDirect.com LLC and West Winds Wellness were targeted with cease and desist letters, which state that the cannabis gifts that they’re offering appear to be central to their business transactions. The non-cannabis items are generally overpriced, the press release notes.
New Jersey’s legalization law establishes the Cannabis Regulatory Commission (CRC) to oversee the market and create licensing rules. CRC Chairperson Dianna Houenou said that the division “is committed to establishing a safe marketplace of cannabis products.”
“Those trying to preempt the rules and transfer unregulated and untested marijuana items jeopardize public health and undermine confidence in the forthcoming regulated cannabis industry,” she said.
“We will not allow vendors to misrepresent what they’re selling,” Kaitlin Caruso, acting director of the state’s Division of Consumer Affairs, said. “Under our consumer protection laws, vendors are subject to fines and penalties for making false or misleading statements about what they’re selling. We have warned these companies about our concerns, and to stop conduct that could violate our laws.”
New Jersey’s attorney general has been proactive about cannabis reform implementation since the legalization bill was enacted.
The day after Gov. Phil Murphy (D) signed bills to legalize and decriminalize marijuana, Grewal directed prosecutors to drop cases for cannabis-related offenses and issued separate guidance for police on how to proceed under the updated laws.
The attorney general also encouraged prosecutorial discretion for marijuana cases in earlier memos prior to the bill’s signing.
Texas Governor Signs Medical Marijuana Expansion Bill
Texas Gov. Greg Abbott (R) signed a bill to modestly expand the state’s limited medical marijuana program on Tuesday.
The legislation adds cancer and post-traumatic stress disorder to the list of conditions that qualify patients to legally access cannabis. It also doubles the amount of THC concentration that is allowed, from 0.5 percent to one percent.
As originally passed in the House, the bill would have also included chronic pain as a qualifying condition, but that was removed by the Senate and was not re-added in a conference committee. The House-approved version also increased the THC limit to five percent, but that too was watered down in the Senate.
Abbott has not yet commented on a separate piece of drug policy reform legislation that the legislature also passed to require the state to study the therapeutic potential of psychedelics like psilocybin and MDMA.
Abbott first announced he would sign the cannabis bill in a Twitter post last week.
Veterans could qualify for medical marijuana under new law.
I will sign it.https://t.co/KkoC15Ur66
— Greg Abbott (@GregAbbott_TX) June 11, 2021
Separate bills to reduce penalties for possessing cannabis concentrates, revise the state’s hemp program and broadly decriminalize marijuana possession also advanced this year—but they did not make it over the finish line by the session’s end.
Partly because of those failures, a newly formed progressive coalition that’s being led by two former congressional candidates said last week that it plans to take cannabis and other issues directly to voters by putting reform measures on local ballots across the state.
Abbott did not sign additional legislation to clarify that a positive marijuana test alone is not sufficient criteria for removing a child from their home. But he didn’t veto it, either, and it was enacted without the his signature last month and takes effect on September 1, 2021.